AGI-134

• Description:

  AGI-134 is a fully synthetic alpha-Gal glycolipid. AGI-134 invokes CD8+ T cell-mediated immunity. AGI-134 induces tumor cell destruction and phagocytosis[1].

• UNSPSC:

  12352005

• Target:

  Biochemical Assay Reagents

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/agi-134.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OC[C@@H](O[C@H]([C@@H]([C@H]1O)NC(C)=O)OCCCNC(CCCCC(NCCOP(OC[C@@H](COC(CCCCCCC/C=C\CCCCCCCC)=O)OC(CCCCCCC/C=C\CCCCCCCC)=O)(O)=O)=O)=O)[C@H]1O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@H]3O[C@@H]([C@@H]([C@@H]([C@H]3O)O)O)CO)O

• Molecular Formula:

  C70H126N3O26P

• Molecular Weight:

  1456.73

• References & Citations:

  [1]Irit Carmi LEVY, et al. Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors. WO2019229745A1. 2019.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [1821461-84-0]